Digest Network Come funziona
Network
/
Società
Sy
Non verificato

Synthekine Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

9 comunicati stampa

Guarda tutti i comunicati
26/02/2026
Mercato del lavoro
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
Fonte
Synthekine Inc.
Emittente
Business Wire
1.00
0
23/02/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato del lavoro
Synthekine Appoints Biotechnology and Pharmaceutical Industry Veteran John A. Orwin as Chair of its Board of Directors
Fonte
Synthekine Inc.
Emittente
Business Wire
1.00
0
13/11/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
First Patient Dosed in SYNERGY-101, a Global, Randomized Phase 2 Clinical Trial of STK-012 in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
Fonte
Synthekine Inc.
Emittente
Business Wire
1.00
0
07/11/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer
Fonte
Synthekine Inc.
Emittente
Business Wire
1.00
0
30/10/2025
Scienza
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Oncologia
Analisi di mercato
Synthekine Announces Late-Breaking Oral Presentation of Initial Clinical Data of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous NSCLC at SITC 2025 Annual Meeting
Fonte
Synthekine Inc.
Emittente
Business Wire
1.00
0
09/12/2024
Scienza
Medicina - Varie
Biotecnologia
Sanità
Salute
Farmaceutica
Oncologia
Eventi
Fiere
Industria
Synthekine Presents Positive Initial Results from Phase 1 Clinical Trial of CD19 CAR-T (SYNCAR-001) and Orthogonal IL-2 (STK-009) Combination Therapy for Treatment of Hematologic Malignancies at ASH 2024 Annual Meeting
Fonte
Synthekine Inc.
Emittente
Business Wire
1.00
0
15/11/2024
Eventi
Industria
Oncologia
Salute
Sanità
Scienza
Biotecnologia
Synthekine to Present Preclinical Data for CD19 CAR-T (SYNCAR-001) Empowered by Orthogonal IL-2 (STK-009) Without Lymphodepletion at American College of Rheumatology (ACR) Convergence 2024
Fonte
Synthekine Inc.
Emittente
Business Wire
1.00
0
08/11/2024
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Synthekine Announces Presentation of New Translational Data from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Fonte
Synthekine Inc.
Emittente
Business Wire
1.00
0
04/09/2024
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Medicina - Varie
Synthekine Granted U.S. FDA Fast Track Designation for CD19 CAR-T and Orthogonal IL-2 Investigational Therapy, SYNCAR-001 + STK-009, for the Treatment of Lupus Without Lymphodepletion
Fonte
Synthekine Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0